some specific chromosomal aberrations of hematologic malignancies in 80 iranian population
Authors
abstract
introduction: most of the hematologic malignancies are heterogenous with regard to morphology, immunophenotype, and genetic rearrangements. multiple recurrent chromosomal aberrations have been identified by conventional cytogenetic analysis, which is now widely recognized as one of the most important diagnostic and prognostic determinants in these patients. patients and methods: bone marrow samples were obtained from 80 patients with different hematologic malignancies. these consisted of 43 cml cases, 27 aml, 9 all and 1 mds. in each case, cells were cultured and conventional cytogenetic analysis was performed. results: among the 80 subjects, 53(66%) were abnormal and 27(34%) showed apparently normal karyotype. the various aberrations in abnormal cases were t(9;22)(q34;q11) in 43 cml (100%), monosomy y in 2 cml (4.6%), monosomy 7 in 1 cml (2.4%), trisomy 8 and t(15;17)(q22;q21) in 2 aml case(7.4%), t(8;21)(q22;q22) in 1 aml (3.7%) and complex karyotype in 2 cml, 1 aml , 1 all and 1 mds (6%). apart from these, some novel chromosomal abnormalities were observed in our study population. conclusion: the difference in the frequency of clonal chromosomal aberrations is probably the result of the applied methods for chromosome preparation and often very poor morphologic chromosome appearance, making the identification of finer structural abnormalities more difficult. furthermore, ongoing cytogenetic studies are warranted in larger groups of hematologic malignancies to identify newly acquired chromosomal aberrations that may aid in cloning novel genes involved in the neoplastic process, ultimately helping in the development of targeted therapeutic drugs.
similar resources
Complications of patients with hematologic malignancies in a selected Iranian population
Background: Hematologic malignancies in childhood and their treatments can cause dental anomalies and jaw bone abnormalities; therefore, the aim of this study was to assess the prevalence of these disorders in children. Methods: This cross-sectional study was conducted on all children diagnosed with hematologic malignancies that referred to in Amirkola Children’s Hospital from 2011 to 2018. Al...
full textEthnic-specific chromosomal aberrations in NSCLC
Purpose: East-Asian (EA) patients with Non Small Cell Lung Cancer (NSCLC) are associated with a high proportion of non-smoking women, EGFR activating somatic mutations, and clinical responses to tyrosine kinase inhibitors. We sought to identify novel molecular differences between EA and Western European (WE) NSCLCs. Experimental Design: 226 EA (90) and WE (136) lung adenocarcinomas were analyze...
full textFungal Infections in Pediatric Patients with Hematologic Malignancies
As the data on the epidemiology and outcome of fungal infections in children with hematologic cancer are limited especially in Iran, this study was aimed to delineate the epidemiologic features and outcome of fungal infections in this population. The medical records of all children with hematologic malignancies diagnosed with a fungal infection from 2005 to 2010 at a tertiary pediatric hospita...
full textHematologic Malignancies
Touch MEdical MEdia 43 Multiple myeloma (MM) is an incurable plasma cell disease that comprises 1 % of all cancers and 10 % of hematologic malignancies. It primarily affects older individuals—the median age at the moment of diagnosis is 70 years—and two-thirds of multiple myeloma patients are over 65 years of age when they are first diagnosed. The outcome of MM patients has significantly improv...
full textHematologic Malignancies in Pregnancy
Cancer and especially hematological cancer during pregnancy is infrequent and its management is difficult for patients and their families, but also for their physicians since two lives with different priorities have to be considered. Treatment should adhere the standard treatment for the specific type and stage of cancer. Small adaptations can be considered in order to avoid adverse effects on ...
full textp53 in hematologic malignancies.
T HE p53 HAS BEEN CHOSEN as molecule of the year for 1993 by the journal Science.' The protein's illustrious history began quietly in 1979, when a 53-kD eukaryotic protein was shown to bind to SV40 large T The protein was named p53 because of its size. Initial studies suggested that p53 was an oncogene because it could transform rodent ~ e l l s . ~ ' ~ The p53 genes used in these studies h...
full textMy Resources
Save resource for easier access later
Journal title:
international journal of hematology-oncology and stem cell researchجلد ۳، شماره ۳، صفحات ۲۸-۳۳
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023